on Cardiol Therapeutics (isin : CA14161Y2006)
Cardiol Therapeutics Inc Receives Updated 'Buy' Rating from First Berlin Equity Research
First Berlin Equity Research has updated its coverage on Cardiol Therapeutics Inc (ISIN: CA14161Y2006). Analyst Christian Orquera reiterated a 'Buy' rating and significantly raised the price target from USD 3.60 to USD 8.50.
The update follows promising topline results from Cardiol’s phase II open-label US pilot study (MAvERIC-Pilot) for CardiolRx, its lead drug candidate for treating recurrent pericarditis (RP). CardiolRx showed efficacy on two key endpoints comparable to FDA-approved rilonacept (Arcalyst) but with a potentially better tolerability and side effect profile.
Given its demonstrated benefits and expected approval, CardiolRx could become a second-line RP therapy. With rilonacept generating USD 233 million in its third year post-approval, CardiolRx is anticipated to exceed this revenue figure due to its strong efficacy and tolerability. The updated valuation incorporates potential EU market expansion, leading to a higher price target of USD 8.50 (€7.80).
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Cardiol Therapeutics news